BIO-TECHNE Corp Company Profile (NASDAQ:TECH)


BIO-TECHNE Corp logoBio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:TECH
  • CUSIP: 87837710
  • Web:
  • Market Cap: $4.12 billion
  • Outstanding Shares: 37,333,000
Average Prices:
  • 50 Day Moving Avg: $105.78
  • 200 Day Moving Avg: $104.37
  • 52 Week Range: $95.68 - $117.42
  • Trailing P/E Ratio: 59.35
  • Foreward P/E Ratio: 28.01
  • P/E Growth: 2.97
Sales & Book Value:
  • Annual Revenue: $541.19 million
  • Price / Sales: 7.61
  • Book Value: $24.32 per share
  • Price / Book: 4.54
  • Annual Dividend: $1.28
  • Dividend Yield: 1.2%
  • EBIDTA: $201.56 million
  • Net Margins: 14.87%
  • Return on Equity: 13.95%
  • Return on Assets: 9.28%
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 2.44%
  • Quick Ratio: 1.90%
  • Average Volume: 175,376 shs.
  • Beta: 0.73
  • Short Ratio: 11.68

Frequently Asked Questions for BIO-TECHNE Corp (NASDAQ:TECH)

What is BIO-TECHNE Corp's stock symbol?

BIO-TECHNE Corp trades on the NASDAQ under the ticker symbol "TECH."

How often does BIO-TECHNE Corp pay dividends? What is the dividend yield for BIO-TECHNE Corp?

BIO-TECHNE Corp announced a quarterly dividend on Tuesday, May 2nd. Investors of record on Friday, May 19th will be paid a dividend of $0.32 per share on Friday, June 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 1.16%. The ex-dividend date is Wednesday, May 17th. View BIO-TECHNE Corp's Dividend History.

How were BIO-TECHNE Corp's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) released its quarterly earnings results on Tuesday, May, 2nd. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The company had revenue of $144.04 million for the quarter, compared to analyst estimates of $142.83 million. BIO-TECHNE Corp had a return on equity of 13.95% and a net margin of 14.87%. The firm's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.01 EPS. View BIO-TECHNE Corp's Earnings History.

Where is BIO-TECHNE Corp's stock going? Where will BIO-TECHNE Corp's stock price be in 2017?

5 brokerages have issued twelve-month target prices for BIO-TECHNE Corp's stock. Their predictions range from $116.00 to $125.00. On average, they expect BIO-TECHNE Corp's stock price to reach $121.25 in the next twelve months. View Analyst Ratings for BIO-TECHNE Corp.

Are investors shorting BIO-TECHNE Corp?

BIO-TECHNE Corp saw a increase in short interest in April. As of April 28th, there was short interest totalling 1,795,129 shares, an increase of 2.1% from the April 13th total of 1,758,792 shares. Based on an average daily volume of 124,395 shares, the short-interest ratio is presently 14.4 days.

Who are some of BIO-TECHNE Corp's key competitors?

Who owns BIO-TECHNE Corp stock?

BIO-TECHNE Corp's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.38%), Vanguard Group Inc. (8.06%), Brown Capital Management LLC (5.76%), Neuberger Berman Group LLC (5.09%), State Street Corp (2.65%) and Janus Capital Management LLC (2.52%). Company insiders that own BIO-TECHNE Corp stock include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Randolph C Steer, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE Corp.

Who sold BIO-TECHNE Corp stock? Who is selling BIO-TECHNE Corp stock?

BIO-TECHNE Corp's stock was sold by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, Wellington Management Group LLP, Brown Capital Management LLC, Pictet Asset Management Ltd., OppenheimerFunds Inc., Janus Capital Management LLC, Summit Creek Advisors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold BIO-TECHNE Corp stock in the last year include John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for BIO-TECHNE Corp.

Who bought BIO-TECHNE Corp stock? Who is buying BIO-TECHNE Corp stock?

BIO-TECHNE Corp's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Neuberger Berman Group LLC, American Century Companies Inc., Vanguard Group Inc., Citadel Advisors LLC, Conestoga Capital Advisors LLC, Mackenzie Financial Corp and Bank of America Corp DE. View Insider Buying and Selling for BIO-TECHNE Corp.

How do I buy BIO-TECHNE Corp stock?

Shares of BIO-TECHNE Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BIO-TECHNE Corp stock cost?

One share of BIO-TECHNE Corp stock can currently be purchased for approximately $110.34.

Analyst Ratings

Consensus Ratings for BIO-TECHNE Corp (NASDAQ:TECH) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $121.25 (9.89% upside)

Analysts' Ratings History for BIO-TECHNE Corp (NASDAQ:TECH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/3/2017Deutsche Bank AGReiterated RatingBuy$115.00 -> $122.00LowView Rating Details
5/3/2017Citigroup IncReiterated RatingBuy$115.00 -> $125.00LowView Rating Details
3/27/2017Janney Montgomery ScottDowngradeBuy -> NeutralHighView Rating Details
11/10/2016Leerink SwannInitiated CoverageOutperform$122.00N/AView Rating Details
8/18/2016Robert W. BairdBoost Price TargetOutperform$115.00 -> $116.00N/AView Rating Details
11/2/2015Craig HallumLower Price TargetBuy$125.00 -> $110.00N/AView Rating Details
10/29/2015StephensDowngradeOverweight -> Equal WeightN/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for BIO-TECHNE Corp (NASDAQ:TECH)
Earnings by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)
Earnings History by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q3 2017$0.93$0.97$142.83 million$144.04 millionViewListenView Earnings Details
2/7/2017Q217$0.85$0.81$134.74 million$131.80 millionViewListenView Earnings Details
10/31/2016Q117$0.79$0.84$127.47 million$130.60 millionViewListenView Earnings Details
8/17/2016Q416$0.96$0.92$129.23 million$134.80 millionViewListenView Earnings Details
5/3/2016Q316$0.89$1.01$122.65 million$131.00 millionViewN/AView Earnings Details
2/2/2016Q216$0.82$0.88$118.59 million$120.90 millionViewN/AView Earnings Details
10/28/2015Q1$0.85$0.79$116.91 million$12.40 millionViewListenView Earnings Details
8/6/2015Q415$0.86$0.87$116.85 million$117.70 millionViewN/AView Earnings Details
5/5/2015Q315$0.91$0.86$119.30 million$114.20 millionViewN/AView Earnings Details
2/3/2015Q215$0.86$0.89$112.73 million$111.90 millionViewN/AView Earnings Details
10/28/2014Q115$0.87$0.85$108.65 million$108.50 millionViewN/AView Earnings Details
8/11/2014Q414$0.85$0.88$91.80 million$92.50 millionViewN/AView Earnings Details
4/28/2014Q314$0.89$0.94$92.50 million$95.60 millionViewN/AView Earnings Details
2/4/2014Q214$0.80$0.75$84.79 million$84.00 millionViewN/AView Earnings Details
10/29/2013Q114$0.80$0.83$82.36 million$85.70 millionViewN/AView Earnings Details
8/6/2013Q4 2013$0.83$0.82$79.71 million$79.50 millionViewN/AView Earnings Details
4/30/2013Q3 2013$0.90$0.88$84.00 million$81.00 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.77$0.74$76.40 million$75.10 millionViewN/AView Earnings Details
10/23/2012$0.79$0.75ViewN/AView Earnings Details
7/31/2012$0.85$0.80ViewN/AView Earnings Details
5/1/2012$0.89$0.90ViewN/AView Earnings Details
1/31/2012$0.79$0.76ViewN/AView Earnings Details
10/25/2011$0.84$0.81ViewN/AView Earnings Details
8/2/2011$0.76$0.76ViewN/AView Earnings Details
5/3/2011$0.80$0.84ViewN/AView Earnings Details
2/1/2011$0.68$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BIO-TECHNE Corp (NASDAQ:TECH)
2017 EPS Consensus Estimate: $3.49
2018 EPS Consensus Estimate: $3.77
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.76$0.81$0.78
Q2 20173$0.81$0.85$0.83
Q3 20173$0.90$0.96$0.93
Q4 20173$0.93$0.98$0.95
Q1 20181$0.88$0.88$0.88
Q2 20181$0.89$0.89$0.89
Q3 20181$0.98$0.98$0.98
Q4 20181$1.02$1.02$1.02
(Data provided by Zacks Investment Research)


Current Dividend Information for BIO-TECHNE Corp (NASDAQ:TECH)
Next Dividend:6/2/2017
Annual Dividend:$1.28
Dividend Yield:1.16%
Payout Ratio:60.95% (Trailing 12 Months of Earnings)
35.36% (Based on This Year's Estimates)
32.49% (Based on Next Year's Estimates)
Dividend Payments by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)

Dividend History by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for BIO-TECHNE Corp (NASDAQ:TECH)
Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 94.74%
Insider Trades by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)
Institutional Ownership by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)
Insider Trades by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2017Roger C LucasDirectorSell100$110.59$11,059.00View SEC Filing  
4/10/2017Roger C LucasDirectorSell100$101.15$10,115.00View SEC Filing  
1/10/2017Roger C LucasDirectorSell100$103.57$10,357.00View SEC Filing  
11/29/2016Karen A HolbrookDirectorSell1,000$106.73$106,730.00View SEC Filing  
11/16/2016Roger C LucasDirectorSell100$105.75$10,575.00View SEC Filing  
9/21/2016Roger C LucasDirectorSell100$108.91$10,891.00View SEC Filing  
9/8/2016John L HigginsDirectorSell1,700$109.83$186,711.00View SEC Filing  
9/8/2016Kevin S. GouldSVPSell524$110.50$57,902.00View SEC Filing  
9/2/2016Robert V BaumgartnerDirectorSell6,467$107.17$693,068.39View SEC Filing  
8/24/2016Robert V BaumgartnerDirectorSell3,533$107.10$378,384.30View SEC Filing  
8/17/2016Roger C. LucasDirectorSell100$113.70$11,370.00View SEC Filing  
7/20/2016Roger C LucasDirectorSell100$111.03$11,103.00View SEC Filing  
6/15/2016Roger C LucasDirectorSell100$112.15$11,215.00View SEC Filing  
5/18/2016Roger C LucasDirectorSell100$102.53$10,253.00View SEC Filing  
5/9/2016Charles A DinarelloDirectorSell5,000$101.91$509,550.00View SEC Filing  
5/6/2016Roger C LucasDirectorSell500$100.24$50,120.00View SEC Filing  
4/20/2016Roger C LucasDirectorSell100$92.40$9,240.00View SEC Filing  
3/16/2016Roger C LucasDirectorSell100$92.90$9,290.00View SEC Filing  
2/5/2016Roger C. LucasDirectorSell5,000$83.68$418,400.00View SEC Filing  
8/13/2015Roger C LucasDirectorSell5,000$106.01$530,050.00View SEC Filing  
6/8/2015Randolph C SteerDirectorSell1,000$99.39$99,390.00View SEC Filing  
2/19/2015Howard V OconnellDirectorSell5,000$95.78$478,900.00View SEC Filing  
12/10/2014Karen A HolbrookDirectorSell1,000$92.40$92,400.00View SEC Filing  
12/9/2014Kevin J ReaganVPSell3,591$89.35$320,855.85View SEC Filing  
12/8/2014Charles A DinarelloDirectorSell3,000$90.44$271,320.00View SEC Filing  
8/14/2014Karen A HolbrookDirectorSell5,000$95.54$477,700.00View SEC Filing  
5/7/2014Howard OconnellDirectorSell5,000$91.00$455,000.00View SEC Filing  
3/4/2014Karen HolbrookDirectorSell5,000$89.83$449,150.00View SEC Filing  
2/27/2014Randolph SteerDirectorSell5,000$88.78$443,900.00View SEC Filing  
11/13/2013Randolph SteerDirectorSell15,000$86.20$1,293,000.00View SEC Filing  
11/8/2013Robert BaumgartnerDirectorSell10,000$87.00$870,000.00View SEC Filing  
11/4/2013Roger C LucasDirectorSell10,000$87.64$876,400.00View SEC Filing  
5/6/2013Howard V OconnellDirectorBuy2,361$65.00$153,465.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BIO-TECHNE Corp (NASDAQ:TECH)
Latest Headlines for BIO-TECHNE Corp (NASDAQ:TECH)
DateHeadline logoShort Interest in BIO-TECHNE Corp (TECH) Increases By 2.1% - May 21 at 5:44 PM logoBio-Techne Corp. : TECH-US: Dividend Analysis : May 19th, 2017 (record date) : By the numbers : May 18, 2017 - May 18 at 12:46 PM logoBIO-TECHNE Corp (TECH) Director Roger C. Lucas Sells 100 Shares - May 12 at 8:48 PM logoBIO-TECHNE Corp (TECH) Given Average Rating of "Buy" by Analysts - May 12 at 8:48 AM logoBio-Techne To Present At The Bank Of America Merrill Lynch Health Care Conference - May 8 at 10:21 AM logoBIO-TECHNE Corp (TECH) Upgraded by TheStreet to B - May 6 at 11:14 PM logoZacks Investment Research Upgrades BIO-TECHNE Corp (TECH) to "Hold" - May 6 at 7:34 AM logoBlog Coverage: Sangamo Receives Special Regulatory Designation from FDA for Three of Its Program - May 5 at 9:06 AM logoBIO-TECHNE Corp (TECH) Given Coverage Optimism Score of 0.18 - May 4 at 5:42 PM logo Brokerages Anticipate BIO-TECHNE Corp (TECH) Will Post Quarterly Sales of $151.11 Million - May 4 at 2:04 PM logoBIO-TECHNE Corp (TECH) Rating Reiterated by Deutsche Bank AG - May 3 at 8:48 PM logoInvestor Network: Bio-Techne to Host Earnings Call - May 3 at 6:23 PM logoCitigroup Inc Reaffirms Buy Rating for BIO-TECHNE Corp (TECH) - May 3 at 3:18 PM logoBio-Techne Q3 Profit Declines, But Results Beat View - Quick Facts - May 3 at 10:24 AM logoEdited Transcript of TECH earnings conference call or presentation 2-May-17 1:00pm GMT - May 3 at 10:24 AM logoBIO-TECHNE Corp to Issue Quarterly Dividend of $0.32 (TECH) - May 2 at 7:38 PM logoBio-Techne (TECH) Q3 2017 Results - Earnings Call Transcript - May 2 at 6:08 PM logoBIO-TECHNE Corp (TECH) Posts Earnings Results, Beats Estimates By $0.04 EPS - May 2 at 3:34 PM logo$0.87 EPS Expected for BIO-TECHNE Corp (TECH) This Quarter - May 2 at 9:06 AM logoThe NIH Looks Trump-Proof - May 2 at 9:04 AM logoBRIEF-Bio-Techne reports Q3 EPS $0.57 - May 2 at 9:04 AM logoBio-Techne Releases Third Quarter Fiscal 2017 Results - May 2 at 9:04 AM logoBIO-TECHNE Corp (TECH) Given Daily Coverage Optimism Score of 0.12 - May 1 at 7:14 PM logoBIO-TECHNE Corp (TECH) Scheduled to Post Quarterly Earnings on Tuesday - April 30 at 7:20 AM logoBio-Techne Corp. – Value Analysis (NASDAQ:TECH) : April 27, 2017 - April 27 at 9:05 PM logoFavorable Media Coverage Very Unlikely to Impact BIO-TECHNE Corp (TECH) Share Price - April 27 at 4:04 PM logoBio-Techne Corp. breached its 50 day moving average in a Bullish Manner : TECH-US : April 26, 2017 - April 26 at 8:53 AM logoBIO-TECHNE Corp (TECH) Lowered to "Sell" at Zacks Investment Research - April 25 at 11:45 AM logoBio-Techne To Present At The Deutsche Bank 42nd Annual Health Care Conference - April 24 at 10:30 AM logoBIO-TECHNE Corp (TECH) Earning Somewhat Positive Press Coverage, Study Shows - April 23 at 6:58 PM logoBIO-TECHNE Corp (TECH) Lowered to Sell at Zacks Investment Research - April 23 at 7:38 AM logoRNAscope Technology Reveals Replication of Zika Virus in Brains of Infants with Microcephaly and Placentas of Women with Pregnancy Losses - April 19 at 8:53 AM logoBio-Techne To Host Conference Call On May 2, 2017 To Announce Third Quarter Financial Results - April 18 at 8:53 AM logoZacks Investment Research Lowers BIO-TECHNE Corp (TECH) to Sell - April 18 at 8:36 AM logoBIO-TECHNE Corp (TECH) Receiving Somewhat Negative Media Coverage, Report Shows - April 17 at 1:40 PM logoBIO-TECHNE Corp (TECH) Receives Average Rating of "Buy" from Analysts - April 17 at 9:56 AM logoBIO-TECHNE Corp (TECH) Receives Media Impact Rating of 0.46 - April 14 at 11:40 AM logo$143.52 Million in Sales Expected for BIO-TECHNE Corp (TECH) This Quarter - April 13 at 1:48 PM logoBIO-TECHNE Corp (TECH) Director Sells $10,115.00 in Stock - April 12 at 8:32 PM logoETFs with exposure to Bio-Techne Corp. : April 7, 2017 - April 7 at 11:28 PM logoJanney Montgomery Scott Downgrades BIO-TECHNE Corp (TECH) to Neutral - March 27 at 5:45 PM logoBIO-TECHNE Corp (TECH) Upgraded by Zacks Investment Research to Hold - March 27 at 8:41 AM logoBIO-TECHNE Corp (TECH) Given Average Rating of "Buy" by Brokerages - March 21 at 12:34 PM logoBIO-TECHNE Corp (TECH) Stock Rating Upgraded by Zacks Investment Research - March 10 at 11:03 AM logoBRIEF-Bio-Techne Corp & Bio-Techne has entered into an exclusive license agreement - March 7 at 8:00 PM logoBio-Techne Signs Exclusive License Agreement with Multiclonal Therapeutics for Adult "Ground-state" Stem Cell Technology - March 7 at 8:48 AM logoInnovative Veterinary Diagnostic Setting A New Standard - March 1 at 9:36 AM logoTECH Makes Bullish Cross Above Critical Moving Average - February 27 at 4:59 PM logoImplied Volatility Surging for Bio-Techne (TECH) Stock Options - February 16 at 8:00 PM logoBIO-TECHNE CORP Financials - February 16 at 8:00 PM



BIO-TECHNE Corp (TECH) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff